Panomifene

Source: Wikipedia, the free encyclopedia.
Panomifene
Clinical data
Other namesGYKI-13504; EGIS-5650
Identifiers
  • 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol
JSmol)
  • C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO
  • InChI=1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+
  • Key:MHXVDXXARZCVRK-WCWDXBQESA-N

Panomifene (

antineoplastic agent by Egis Pharmaceuticals and IVAX Drug Research Institute in the 1990s for the treatment of breast cancer, but it was never marketed.[1][2][3][4][5][6] It reached phase II clinical trials before development was terminated.[2] The drug was described in 1981.[1]

References

  1. ^
    ISBN 978-1-4757-2085-3
    .
  2. ^ a b "Panomifene". AdisInsight. Springer Nature Switzerland AG.
  3. ISBN 978-3-642-58616-3
    .
  4. ISBN 978-3-642-60107-1
    .
  5. ISBN 978-3-319-08482-4
    .
  6. PMID 9328614
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Panomifene&oldid=1191889564"